The field of synthetic biology is currently defined by the ability to write DNA with the same ease that we read it. Oligonucleotide pools—large collections of short, single-stranded DNA or RNA sequences—are the "ink" for this process. Unlike individual custom oligos, these pools allow researchers to synthesize thousands of unique sequences simultaneously. This high-throughput approach is vital for creating the complex genetic libraries required for modern drug discovery, enabling the rapid testing of countless genetic variants in a single experiment.

The Oligonucleotide Pool Market is experiencing significant growth, with the global market size valued at approximately USD 3 billion in 2026. This expansion is primarily driven by the "genomics revolution" and the increasing demand for high-fidelity libraries in CRISPR-Cas9 gene editing and Next-Generation Sequencing (NGS). Manufacturers are now utilizing advanced microfluidic-based electrochemical synthesis to produce pools containing over 100,000 unique sequences with extremely low error rates. These technical milestones are reducing the "cost-per-sequence," making massive genetic screening accessible to both academic researchers and large-scale pharmaceutical firms.